If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
== Academic career == From 1964 to 1968, he was Professor of Chemistry at Purdue University. In 1968, he returned to his alma mater, Cornell University, to become the Peter J. W. Debye Professor of Chemistry. He was elected to the United States National Academy of Sciences in 1982. While at Cornell, McLafferty assembled one of the first comprehensive databases of mass spectra and pioneered artificial intelligence techniques to interpret GC-MS results. His PBM STIRS program has widespread use to save hours of time-consuming work otherwise required to manually analyze GC-MS results.
Valsartan/hydrochlorothiazide, sold under the brand name Diovan HCT among others, is a medication used to treat high blood pressure when valsartan is not sufficient. It is a combination of valsartan, an angiotensin receptor blocker with hydrochlorothiazide, a diuretic. It is taken by mouth. Common side effects include dizziness and headaches. Serious side effects may include allergic reactions, electrolyte abnormalities, and glaucoma. Use in pregnancy is not recommended. The combination was approved for medical use in the United States in 1998. It is available as a generic medication. In 2021, it was the 224th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
== Bibliography == Winstein, Merryl (2017). Successful Cheesemaking™, Step-by-Step Directions and Photos for Making Nearly Every Type of Cheese, (670pp, 800 photos). St. Louis, Missouri: Smooth Stone Press. ISBN 978-0998595955. Robinson, R.K.; Wilbey, R.A. (1998). Cheesemaking practice (3rd ed.). Dordrecht: Kluwer Academic. Banks, J (1998). Cheese (2nd ed.). Early, R. The technology of dairy products. London: Chapman and Hall. Jenkins, Steven (1996). Cheese Primer. New York: Workman Publishing. Tannahill, Reay (2008). Food in History. New York: Three Rivers Press.
Sources: en.wikipedia.org
== Genetics == The gene encoding the enzyme is referred to as DDC is located on chromosome 7 in humans. It consists of 15 exons encoding a protein of 480 amino acids. Single nucleotide polymorphisms and other gene variations have been investigated in relation to neuropsychiatric disorders, for example, a one-base pair deletion at 601 and a four-base pair deletion at 722–725 in exon 1 in relation to bipolar disorder and autism. No direct correlation between gene variation and autism was found. More than 50 mutations of DDC have been correlated with AADC deficiency. This condition is most prevalent in Asia, presumably due to the founder effect. Alternative splicing events and promoters have been observed that lead to various forms of the AADC enzyme. Unique usage of certain promoters leads to transcription of only the first exon to produce an extra-neuronal isoform, and splicing of exon 3 leads to a product devoid of enzymatic activity. Analyses via porcine specimens have elucidated two AADC isoforms – resulting from exclusion of exon 5 and exons 5 and 6 – that lack a portion of the decarboxylating domain.
On April 5, the Iraqi government announced "the complete crushing of acts of sedition, sabotage and rioting in all towns of Iraq." An estimated 25,000 to 100,000 Iraqis were killed in the uprisings. In Kuwait, the Emir was restored, and suspected Iraqi collaborators were repressed. Eventually, over 400,000 people were expelled from the country, including a large number of Palestinians, because of PLO support of Saddam. Yasser Arafat did not apologize for his support of Iraq, but after his death Mahmoud Abbas formally apologized in 2004 on behalf of the PLO. This came after the Kuwaiti government formally forgave the group. There was some criticism of the Bush administration, as they chose to allow Saddam to remain in power instead of pushing on to capture Baghdad and overthrowing his government. In their co-written 1998 book, A World Transformed, Bush and Brent Scowcroft argued that such a course would have fractured the alliance, and would have had many unnecessary political and human costs associated with it. In 1992, the US defense secretary during the war, Dick Cheney, made the same point:
Commonly used spacers and connecting groups include polyether chains, biphenyls and terphenyls, and simple alkyl chains. The chemistry for creating and connecting these units is very well understood. nanoparticles, nanorods, fullerenes and dendrimers offer nanometer-sized structure and encapsulation units. Surfaces can be used as scaffolds for the construction of complex systems and also for interfacing electrochemical systems with electrodes. Regular surfaces can be used for the construction of self-assembled monolayers and multilayers. The understanding of intermolecular interactions in solids has undergone a major renaissance via inputs from different experimental and computational methods in the last decade. This includes high-pressure studies in solids and "in situ" crystallization of compounds which are liquids at room temperature along with the use of electron density analysis, crystal structure prediction and DFT calculations in solid state to enable a quantitative understanding of the nature, energetics and topological properties associated with such interactions in crystals.
Sources: en.wikipedia.org
==== Eliminated in primary ==== Randy Adams, car dealership owner Josh Cortez, former advisor to U.S. representative Monica De La Cruz (previously ran in the 28th district) Mark Eberwine, home inspector Jay Furman, physician and nominee for the 28th district in 2024 (previously ran in the 28th district) Vanessa Hicks-Callaway Ryan Krause, executive coach Larry LaRose, veteran Rod Lingsch, retired pilot Steven Wright, retired deputy sheriff and nominee for this district in 2024
== Treatment == The treatment to battle the disease chorea-acanthocytosis is completely symptomatic. For example, botulinum toxin injections can help to control orolingual dystonia. Deep brain stimulation is a treatment that has varied effects on the people suffering from the symptoms of this disease, for some it has helped in a large way and for other people it did not help whatsoever, it is more effective on specific symptoms of the disease. Patients with chorea-acanthocytosis should undergo a cardiac evaluation every five years to look for cardiomyopathy.
Post-translational modifications (PTMs) are the covalent processes of changing proteins following their synthesis, and release from ribosomes. PTMs are reversible editing events used and carried out in the overall process of post-translational regulation – the control of the levels of active protein; an irreversible event is proteolysis (protein degradation). PTMs enable the protein's function to be diversified and extended beyond the dictates of transcription. As of 2023 there are more than 650 known types of PTM. PTMs are also prokaryotic processes. PTMs may involve enzymes or occur spontaneously. Proteins are created by ribosomes, which translate mRNA into polypeptide chains, which may then change to form the mature protein product, which is then released from the ribosome. PTMs are important components in cell signalling, as for example when prohormones are converted to hormones. Post-translational modifications can occur on the amino acid side chains or at the protein's C- or N- termini. They can expand the chemical set of the 22 amino acids by changing an existing functional group or adding a new one such as phosphate. Phosphorylation is highly effective for controlling the enzyme activity and is the most common change after translation. Many eukaryotic and prokaryotic proteins also have carbohydrate molecules attached to them in a process called glycosylation, which can promote protein folding and improve stability as well as serving regulatory functions.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.